Background: We examined associations of three markers of subclinical cardiovascular disease (intimal-medial thickening, coronary artery calcification , and ankle-brachial index) with changes in self-reported walking over time. Methods: Data were from 6,490 Multi-Ethnic Study of Atherosclerosis participants (aged 45-84 years), free of clinical cardiovascular disease at baseline. Outcomes, assessed four times over 11 years, included self-reported walking pace (none to striding pace; score, 0-4) and total walking time (minutes/week). Linear generalized estimating equation models estimated associations of baseline intimal-medial thickening (zscored), coronary artery calcification (Agatston units), and ankle-brachial index (ratio of ankle-to-arm systolic blood pressure) with walking pace and walking time modeled continuously in separate analyses. Results: Median follow-up was 9.2 years (maximum, 11.4). Walking pace (estimate, −0.042 points [95% CI; −0.048, −0.036], p < 0.0001) and walking time (estimate, −4.71 minutes [95% CI: −8.54, −0.88], p = 0.016) decreased yearly. Greater baseline intimal-medial thickening related to faster decline in walking pace in multivariable analyses: walking pace score decreased 0.004 points (95% CI: −0.008, −0.001) more per year for each 1-SD higher intimal-medial thickening z-score, equivalent to an additional 10% slower yearly walking. Greater coronary artery calcification was associated with slower walking but inconsistently related to decline in walking pace. Higher ankle-brachial index was associated with faster baseline walking pace (estimate, 0.043 points [95% CI: 0.027, 0.059] per 1-SD) but unrelated to changes in walking pace. Cardiovascular disease measures were unrelated to total walking time. Conclusions: Greater subclinical cardiovascular disease is associated with prevalent slower self-reported walking pace in middle-aged and older adults but has limited impact on changes in walking over time.
chronic conditions and multimorbidity exacerbate these effects, especially among the very old (7) . These limitations are not restricted to patients with overt clinical disease but may develop well before onset of a chronic condition. Epidemiological studies show that individuals who subsequently experience myocardial infarction or stroke showed declines in basic physical functions during the preclinical phase, before acute clinical manifestation of these conditions (8, 9) . Such observations raise the question of whether subclinical cardiovascular disease (CVD) contributes to changes in basic physical functions. Older adults with subclinical CVD but without clinically manifest disease experience greater frailty and adverse health effects (10, 11) . Available cross-sectional evidence links subclinical CVD with slower walking speed and poorer performance on tests of balance and physical function (12) (13) (14) (15) . However, the exact role of subclinical CVD in age-associated declines in basic physical functions and, in mobility in particular, remains mostly unknown.
This study examined three markers of subclinical CVD in relation to declines in mobility, assessed by self-reported walking pace and time, over 11 years of follow-up in the Multi-Ethnic Study of Atherosclerosis (MESA), which includes a large, diverse cohort. Because age-related mobility declines are known to vary by sex and race/ethnicity (16, 17) , we examined whether associations differed for men and women or across racial/ethnic groups.
Method

Study Design
MESA is a population-based prospective cohort study of risk factors for subclinical atherosclerosis (18) Eligible participants had to be asymptomatic for clinical CVD at enrollment. All provided written informed consent, and institutional review boards at participating institutions approved the study. At visit 1 (baseline), detailed questionnaires assessing demographics, medical history, physical activity, neighborhood characteristics, lifestyle traits, and psychosocial factors were administered; standard measurements of height, weight, and blood pressure and a 12-hour fasting blood sample were obtained. Between September 2002 and February 2012, four follow-up visits were completed using similar study protocols.
Participants
MESA participants with available data on subclinical CVD measures and self-reported walking pace and walking time were eligible for the current analyses. Persons who did not respond to both walking pace and walking minutes questions (n = 19), reported no walking at all at baseline (n = 299), or were missing information on education (n = 6) were excluded; 6,484 persons were eligible for analyses of walking pace, and 6,490 were eligible for analyses of walking time. Compared to those included in the analyses, persons excluded because they reported no walking at baseline predominantly were black (55.9%) and older (mean [ 
Measures
Outcome Variables
The change in self-reported walking pace over time was our primary outcome. Self-reported walking pace was assessed at MESA visits 1, 2, 3, and 5 with a single question, "When you walk outside your home, what is your usual pace?" Response options (0-4) were none [0], casual strolling (up to 2 mph) [1] , average or normal (2-3 mph) [2] , fairly briskly (4-5 mph) [3] , and brisk or striding (more than 5 mph) [4] . Consistent with a prior MESA report (20) , responses were modeled continuously. For descriptive purposes only, we also created a three-level ordinal variable representing slow (<2 mph), medium (2-3 mph), and fast walking pace (>3 mph) by collapsing the bottom two and top two response options, respectively, to define slow and fast walking pace. In addition, total minutes of walking per week were determined based on responses to two items from the MESA Typical Week Physical Activity survey (19) that asked respondents to indicate how many minutes in a typical week they walked to get places and walked for exercise. Hereafter, this variable is referred to as total walking time.
Subclinical CVD Three indicators of subclinical CVD from the baseline MESA visit were predicted: carotid artery intimal-medial thickness (IMT), coronary artery calcium (CAC), and ankle-brachial index (ABI). Details have been published (18, 19) . IMT was measured with high-resolution B-mode ultrasonography in the near and far walls of the right and left common carotid artery (CCA) and internal carotid arteries (ICA). Digitized images were analyzed centrally (20) . A single averaged z-score was created by summing the average maximum IMT values from the CCA and ICA after standardization and dividing by the standard deviation of the sum. A single IMT value was used if only one of the two measures was available. CAC was assessed by chest-computed tomography, and a mean phantom-adjusted Agatston score was computed as the sum of calcium measures from four arterial sites. ABI was obtained by measuring blood pressure with an appropriate-sized cuff in both arms and both legs after a 5-minute supine rest. The minimum ratio of ankle systolic blood pressure (SBP) to arm SBP was calculated for both sides; the smallest ratio was the ABI used in analyses. ABI values <1.0 are considered low, with values <0.9 indicative of peripheral arterial disease (PAD); abnormally high values (≥1.4) reflect arterial stiffening likely due to noncompressible arteries (21) .
Covariates
Covariates, assessed at baseline, included demographics (age, field center, race/ethnicity, sex, marital status, education); CVD risk factors (body mass index [BMI], resting SBP and diastolic blood pressure [DBP], use of antihypertensives and lipid-lowering medications [eg, statins], total and high-density lipoprotein cholesterol and triglycerides measured from fasting blood specimens using standard assays, Friedewald-calculated (22) low-density lipoprotein cholesterol, and diabetes status based on ADA criteria (23)); health behaviors (alcohol use, smoking, and physical activity (19) ); relevant chronic conditions; and resting heart rate.
Data Analysis
Descriptive statistics were computed on predictors and covariates of interest for all participants and by self-reported walking pace at baseline. First, linear generalized estimating equation (GEE) models were estimated to evaluate changes in self-reported walking pace and total walking time, adjusting for study site and demographics. Linear GEE models were selected for primary analyses as they also are appropriate for use with ordinal outcomes with ≥5 categories (24) and provide the most straightforward interpretation of results (see Supplementary Methods for details on alternative models considered and rationale for using linear GEE). A second set of GEE models assessed the relation of baseline levels of subclinical CVD with a change in self-reported walking pace and total walking time in separate models. Repeated outcome measures of walking pace and walking time were treated as continuous variables. Minimally (model 1) and risk factor-adjusted models (models 2 and 3) were estimated with IMT, CAC, and ABI variables modeled continuously in 1-SD increments and time modeled continuously in years. Analyses of CAC excluded persons with extreme values (>95th percentile), since the primary analysis focused on continuous CAC and CAC values are highly skewed. Tests for linearity in the associations with higher order terms for the subclinical CVD measures and for time did not consistently improve model fit for any subclinical measures. In secondary analyses, the subclinical CVD measures were modeled as categorical variables, with IMT modeled in approximate quartiles based on the distribution of values, CAC modeled by Agatston scores (0; >0 to <100; 100 to <400; and ≥400), and ABI modeled as low (<1.0) versus normal range (1.0 to <1.4). 0.7% of participants with abnormally high ABI (≥1.4), indicative of noncompressible arteries (21) , was excluded from all analyses of ABI and walking. To evaluate whether subclinical CVD was related to accelerated changes in walking (pace and minutes walked) over time, an interaction term between subclinical CVD and time (days since baseline visit) was the main independent variable in each model in both continuous and categorical analyses. GEE models were run using an unstructured covariance pattern and robust standard errors.
Model 1 was adjusted for demographics, with interaction terms for time with age and study site. Model 2 also adjusted for health behaviors, BMI, and BMI*time. The fully adjusted model 3 added clinical CVD risk factors, chronic conditions, and heart rate. We also evaluated three-way interactions of the subclinical disease exposure*time*(age, sex, or race/ethnicity). Sensitivity analyses were conducted that added inverse-probability-of-attrition-weights (IPAW) (25) to account for any potential differential attrition that may have arisen during follow-up in MESA (see Supplementary Methods).
Results
Baseline characteristics are shown in Table 1 for all participants and by self-reported walking pace (slow/medium/fast) at visit 1. Participants who reported a fast walking were younger, more likely to be male, white, married or living with a partner, collegeeducated, with a generally healthier CVD risk profile; they reported more minutes of weekly total walking time. The average follow-up time was 7.3 years (median = 9.2 years; range = 0.0-11.4).
Across four MESA visits, an increasing proportion of respondents reported a slow walking pace (see Figure 1) ; 36.1% were walking slowly by visit 5 (~11 years later), and fewer respondents reported a fast walking pace over time.
Separate GEE models of walking pace and time showed declines over time. 
Subclinical CVD and Self-Reported Walking Pace
With IMT modeled continuously ( Table 2 , top rows), a significant IMT*time interaction showed that baseline IMT was related to faster yearly declines in walking pace in minimally and fully adjusted models (models 1-3). Each 1-SD higher IMT value at baseline related to a 0.004-point lower walking pace score per year (model 3), equivalent to an additional 10% slower yearly walking pace beyond effects of time. Results were relatively unchanged in the sensitivity analyses using IPAW (IMT*time estimate, −0.006 (95% CI: −0.009, −0.003) (data not shown).
Analysis of IMT values in quartiles showed an interaction with time for the 4th quartile group in each model (Supplementary  Table 1 ); the annual decline in walking pace was largest for those with the highest baseline IMT values (ie, 4th quartile group), whose reported walking pace declined by 0.01 points per year, compared to the referent group (ie, the 1st quartile) (p = .02 in model 3). Associations did not vary by age, sex, or race/ethnicity (data not shown). Comparing the magnitude of change in walking pace for the top IMT quartile with the average effect of age on walking pace provides perspective. Each 1-year increase in age in the same model is associated with a 0.035-point decline per year; thus, the impact of IMT on walking pace is approximately one-third of a year, or 4 months. Multiplying these values by 10 suggests those with the greatest IMT in their carotid arteries would experience an additional 2.5-3 years of decline in walking pace over a decade.
Results for the association of baseline CAC with the change in walking pace over time were inconsistent. A CAC*time interaction ( Table 2 , middle rows) showed that each 1-SD higher Agatston score was associated with a 0.003-point (95% CI: −0.006, −0.0002) greater decrease in walking pace score per year (model 1) that was unchanged by adding covariates (models 2 and 3). However, analysis of CAC in categories (Supplementary Table 2) shows a cross-sectional association but no evidence for an interaction with time; those with CAC values ≥400 had a 0.121-point slower walking pace score (model 1) compared to those without calcification; this association was reduced with covariate adjustment and no longer statistically significant in the fully adjusted model (model 3). No consistent differences by age, sex, or race/ethnicity were noted (data not shown). Using IPAW (data not shown) also shows no evidence for an interaction with time.
All ABI*time interactions were nonsignificant ( Table 2 , bottom rows) without or with IPAW (data not shown), but a cross-sectional association was observed. Each 1-SD higher ABI value related to faster baseline walking pace (around 0.04 points) in all models. Analysis of ABI < 1 versus 1.0 to <1.4 (Supplementary Table 3) showed that participants with low ABI had significantly slowed walking pace, equivalent to the impact of aging 3.9 years on walking pace (model 1), and little changed with risk factor adjustments. No consistent differences by age, sex, or race/ethnicity were observed (data not shown).
Subclinical CVD and Self-Reported Walking Time
Analyses of IMT, CAC, and ABI showed no subclinical CVD*time interactions (p-values > .11) and no main effects (p-values > .06) for total walking time, without or with risk factor adjustment.
Other variables in the models showed expected associations with walking. At baseline, smoking, alcohol consumption, and use of antihypertensive medications were associated with slower walking pace, whereas higher education, higher resting DBP, more physical activity, and higher HDL cholesterol were cross-sectionally associated with a faster pace. Higher BMI and older age were associated with a more rapid decline in yearly walking pace (data not shown).
Discussion
In this study of middle-aged and older community-dwelling adults without a history of clinical CVD, carotid atherosclerosis, coronary calcium, and ABI were related to self-reported walking pace. All disease measures showed cross-sectional associations with walking pace, but carotid atherosclerosis was the only measure consistently related to declines in walking over time. Those with the most carotid atherosclerosis at baseline showed significantly greater yearly declines in self-reported walking pace in adjusted analyses. Our findings suggest that the impact of IMT on walking pace is equivalent to aging 4 months; over the span of a decade, those with the highest IMT values at baseline would be expected to experience 2.5-3 years additional decline in walking pace. Self-reported walking speed has been identified as a strong risk factor for incident stroke (26) . More objective data on walking speed are needed to fully evaluate the clinical impact of our study findings. Subclinical disease was not related to self-reported time spent on walking. None of the observed associations varied by sex or race/ethnicity.
Extent of IMT in the carotid arteries is considered as an indicator of overall atherosclerotic burden. Average ICA and CCA IMT values were greatest among participants with the slowest walking pace at baseline (Table 1) ; those with the slowest walking pace had higher CAC scores and lower ABI values, further documenting greater burden of subclinical CVD in this group. Only IMT was consistently related to a decline in walking pace; reasons for this are unclear. IMT in the carotid arteries may affect cerebral blood flow, which, if diminished, could affect balance and motor function and, thus, walking. We did not measure cerebral blood flow and the overall impact of IMT on yearly declines in walking pace was small. However, effects of IMT on walking likely accumulate, so even small decrements related to the extent of carotid atherosclerosis may become clinically meaningful over time. Small differences at the individual level can have a large population impact (27) ; so, understanding the relation of subclinical disease with incremental changes in walking is valuable. Additionally, research is needed to examine mechanisms that could explain how subclinical disease influences walking and other indicators of mobility.
Prior studies have reported cross-sectional associations of subclinical CVD with measures of gait, balance, and physical performance (12) (13) (14) (15) . Our findings are consistent with these reports. Fewer longitudinal studies have been published, but available studies largely have focused on PAD. Asymptomatic PAD has been associated with accelerated mobility decline in persons with known PAD (28) and with declines in self-reported functional status in a selected community sample of relatively healthy adults (29) . Just 3% of our sample had abnormally low ABI values (<0.90) that suggest PAD, so we did not do a PAD subgroup analysis, but our analysis of walking pace and ABI revealed only cross-sectional relations. Additional research is needed to better understand the role of subclinical CVD, including PAD, in mobility changes. Reciprocal associations between subclinical CVD and mobility are likely. Greater disease could lead to slower walking and, ultimately, reduced mobility; in turn, reduced mobility and presumably concomitant reductions in aerobic activity may contribute to progression of disease. Notably, persons with evidence of PAD or CAC that has been detected clinically commonly are prescribed walking as an important part of their treatment regimen, which could attenuate associations such as those we investigated. MESA participants, as a condition of enrollment, were free of clinical CVD and the study did not obtain data on whether walking or other exercise had been specifically prescribed to address any elevations in risk factors or clinical signs or symptoms. Physical activity was a significant covariate in the models in which it was included although the associations of subclinical CVD with walking pace were independent of physical activity. A prior cross-sectional report from MESA found that increasing levels of moderate to vigorous physical activity were associated with ABI but not IMT or CAC (19) . Further longitudinal investigations are needed to disentangle these interrelationships.
We did not find significant associations between subclinical CVD and total minutes of time spent on walking weekly, one of our indicators of mobility. The measure, part of the MESA physical activity assessment (19) , is based on self-report of the time spent on walking to get places as well as for exercise. The accuracy of this measure could be limited. Participants' responses could reflect availability of private or public transportation, proximity to frequented places, and weather constraints or other unmeasured influences, all of which could influence the amount of time spent on walking separately from health factors that might influence walking. The average total minutes walked per week in our sample was ~70 minutes/day at baseline, although the data were very skewed (median minutes walked per week at baseline were ~45 minutes/day). However, the total minutes walked per week varied by self-reported walking pace, as might be anticipated (see Table 1 ), with higher average number of minutes walked with faster pace. Additionally, a small but significant annual decline in overall time spent on walking was observed. Self-reported physical activity is not highly correlated with more objective indicators of activity levels (30, 31) , and it is likely that objective indicators of walking, for example, via pedometers and other wearable fitness devices, would provide more stable and reliable estimates of total walking time as well as walking speed.
Strengths and Limitations
Study limitations include a lack of objectively measured physical function at any study visit. Our proxy indicators of mobility, selfreported walking pace, and total time spent on walking are subjected to recall bias and can be easily over-or underestimated. We also lack assessments of pre-existing physical impairments or whether participants developed any impairment over time that would compromise their mobility in general or their ability to walk specifically. However, MESA has several strengths. Validated assessments of subclinical CVD were used and the study includes a large, racially, and ethnically diverse sample, thereby enhancing generalizability.
In summary this study shows that in middle-aged and older adults without clinically manifest CVD, higher levels of subclinical CVD are associated with poorer self-reported walking pace. As expected, walking declined over time in this cohort, but only the extent of atherosclerosis in the carotid arteries was related to a more rapid decline in walking pace. Research is needed to understand how specific vascular disease processes affect functional outcomes and declining mobility as people age. 
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